Follistatin-344
Follistatin-344 is a naturally occurring glycoprotein that binds and neutralizes myostatin — the primary protein that limits muscle growth. By suppressing myostatin activity, follistatin-344 removes a key biological brake on muscle hypertrophy and has significant research interest in muscle-wasting diseases and athletic performance.
Common Dosage
100mcg daily for 10-30 days (research cycles)
Category
Muscle Growth
- Myostatin inhibition
- Enhanced muscle hypertrophy
- Improved strength output
- Muscle preservation in wasting conditions
- Potential anti-fibrotic effects in muscle tissue
Follistatin was first identified in 1987 in follicular fluid of ovarian follicles, originally characterized as an inhibitor of FSH (follicle-stimulating hormone) secretion — hence the name. The 344-amino-acid isoform (Follistatin-344, or FST-344) emerged as particularly relevant for myostatin inhibition when researchers discovered that follistatin neutralizes myostatin — a TGF-β superfamily member that acts as a biological brake on muscle growth. The scientific community's interest intensified dramatically after a landmark 2004 study by Rodger Wyeth and colleagues showed that mice with four times normal muscle mass could be produced through myostatin knockout, and that follistatin gene delivery in adult mice produced similarly dramatic muscle increases. This led to significant interest in gene therapy approaches to muscle-wasting diseases and, subsequently, to research peptide interest in the follistatin-344 isoform.
Follistatin-344 is a glycoprotein that binds myostatin (GDF-8) and other TGF-β family members (including activin A, GDF-11) with high affinity, sequestering them and preventing receptor activation. Myostatin normally signals through ActRIIB receptors to activate SMAD2/3 transcription factors, which upregulate genes that limit protein synthesis and promote protein degradation — the molecular brake on muscle growth. By neutralizing myostatin, follistatin-344 removes this brake, allowing AKT/mTOR signaling to drive protein synthesis without the opposing catabolic signal. The net effect is enhanced satellite cell activation, increased myofiber nuclei, and sustained hypertrophy beyond normal biological limits.
- Muscular dystrophy — Duchenne and Becker MD gene therapy trials using AAV-follistatin vectors
- Sarcopenia and age-related muscle loss prevention
- Post-surgical or injury-related muscle atrophy recovery
- ALS (amyotrophic lateral sclerosis) — preserving motor neuron-innervated muscle mass
- Cachexia in cancer patients — preserving lean mass during wasting
- Spinal muscular atrophy (SMA) adjunct research
- Athletic performance research — skeletal muscle hypertrophy ceiling exploration
Muscular Dystrophy Gene Therapy Trials
A Phase 1/2a clinical trial using AAV-follistatin gene delivery to biceps brachii muscles in Becker muscular dystrophy patients showed significantly improved muscle performance scores, increased fiber cross-sectional area on biopsy, and no serious adverse events at 12-month follow-up. The approach is now advancing in Duchenne MD trials.
Animal Model Muscle Gains
In the classic 2004 Wyeth et al. study, follistatin gene delivery to adult mice (following a myostatin deletion background) produced muscles 117% larger than wild-type controls. Even in normal mice, single-muscle follistatin injection produced approximately 327% increase in fiber cross-sectional area — the most dramatic muscle hypertrophy effect demonstrated with any single intervention in the literature.
Sarcopenia Research
Aged rodent studies using recombinant follistatin protein showed significant reversal of age-related muscle mass decline and functional strength improvements in grip and rotarod testing. The researchers noted that follistatin also reduced adipose tissue infiltration into aging muscle — a phenomenon (myosteatosis) that contributes to functional decline independent of fiber atrophy.
- Organ enlargement risk — follistatin inhibits multiple TGF-β family members including activin, which regulates heart and other organ growth; supraphysiologic levels may contribute to cardiac hypertrophy or organ enlargement
- Cancer risk — myostatin and activin are tumor-suppressive in some contexts; sustained inhibition may theoretically promote growth of dormant tumors or accelerate existing malignancies
- No long-term human safety data for peptide administration (as opposed to targeted gene therapy)
- Gene therapy approaches are not equivalent to injectable peptide approaches — extrapolating safety from gene therapy trials to peptide use requires caution
- FSH suppression — follistatin was originally characterized as an FSH inhibitor; reproductive effects are possible with systemic exposure
- Inconsistent purity and potency in research peptide market — follistatin-344 is particularly difficult to synthesize correctly
- Organ enlargement risk at high doses
- Unknown long-term cardiovascular effects
- Potential to accelerate smooth muscle overgrowth